A Bayesian adaptive phase I–II trial design for optimizing the schedule of therapeutic cancer vaccines

Kristen M. Cunanan, Joe Koopmeiners

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Phase I–II clinical trials refer to the class of designs that evaluate both the safety and efficacy of a novel therapeutic agent in a single trial. Typically, Phase I–II oncology trials take the form of dose-escalation studies, where initial subjects are treated at the lowest dose level and subsequent subjects are treated at progressively higher doses until the optimal dose is identified. While dose-escalation designs are well-motivated in the case of traditional chemotherapeutic agents, an alternate approach may be considered for therapeutic cancer vaccines, where an investigator's main objective is to evaluate the safety and efficacy of a set of dosing schedules or adjuvant combinations rather than to compare the safety and efficacy of progressively higher dose levels. We present a two-stage, Bayesian adaptive Phase I–II trial design to evaluate the safety and efficacy of therapeutic cancer vaccines. In the first stage, we determine whether a vaccination schedule achieves a minimum level of performance by comparing the toxicity and immune response rates to historical benchmarks. Vaccination schedules that achieve a minimum level of performance are compared using their magnitudes of immune response. If the superiority of a single schedule cannot be established after the first stage, Bayesian posterior predictive probabilities are used to determine the additional sample size required to identify the optimal vaccination schedule in a second stage.

Original languageEnglish (US)
Pages (from-to)43-53
Number of pages11
JournalStatistics in Medicine
Volume36
Issue number1
DOIs
StatePublished - Jan 15 2017

Fingerprint

Cancer Vaccines
Vaccine
Dose
Cancer
Appointments and Schedules
Schedule
Efficacy
Vaccination
Safety
Immune Response
Evaluate
Therapeutics
Benchmarking
Phase III Clinical Trials
Oncology
Sample Size
Toxicity
Clinical Trials
Alternate
Research Personnel

Keywords

  • Bayesian adaptive design
  • multiple outcomes
  • phase I–II
  • randomized trial
  • therapeutic cancer vaccines
  • two-stage

PubMed: MeSH publication types

  • Journal Article
  • Research Support, Non-U.S. Gov't

Cite this

A Bayesian adaptive phase I–II trial design for optimizing the schedule of therapeutic cancer vaccines. / Cunanan, Kristen M.; Koopmeiners, Joe.

In: Statistics in Medicine, Vol. 36, No. 1, 15.01.2017, p. 43-53.

Research output: Contribution to journalArticle

@article{3cca18890127417391daea81a324e0ff,
title = "A Bayesian adaptive phase I–II trial design for optimizing the schedule of therapeutic cancer vaccines",
abstract = "Phase I–II clinical trials refer to the class of designs that evaluate both the safety and efficacy of a novel therapeutic agent in a single trial. Typically, Phase I–II oncology trials take the form of dose-escalation studies, where initial subjects are treated at the lowest dose level and subsequent subjects are treated at progressively higher doses until the optimal dose is identified. While dose-escalation designs are well-motivated in the case of traditional chemotherapeutic agents, an alternate approach may be considered for therapeutic cancer vaccines, where an investigator's main objective is to evaluate the safety and efficacy of a set of dosing schedules or adjuvant combinations rather than to compare the safety and efficacy of progressively higher dose levels. We present a two-stage, Bayesian adaptive Phase I–II trial design to evaluate the safety and efficacy of therapeutic cancer vaccines. In the first stage, we determine whether a vaccination schedule achieves a minimum level of performance by comparing the toxicity and immune response rates to historical benchmarks. Vaccination schedules that achieve a minimum level of performance are compared using their magnitudes of immune response. If the superiority of a single schedule cannot be established after the first stage, Bayesian posterior predictive probabilities are used to determine the additional sample size required to identify the optimal vaccination schedule in a second stage.",
keywords = "Bayesian adaptive design, multiple outcomes, phase I–II, randomized trial, therapeutic cancer vaccines, two-stage",
author = "Cunanan, {Kristen M.} and Joe Koopmeiners",
year = "2017",
month = "1",
day = "15",
doi = "10.1002/sim.7087",
language = "English (US)",
volume = "36",
pages = "43--53",
journal = "Statistics in Medicine",
issn = "0277-6715",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - A Bayesian adaptive phase I–II trial design for optimizing the schedule of therapeutic cancer vaccines

AU - Cunanan, Kristen M.

AU - Koopmeiners, Joe

PY - 2017/1/15

Y1 - 2017/1/15

N2 - Phase I–II clinical trials refer to the class of designs that evaluate both the safety and efficacy of a novel therapeutic agent in a single trial. Typically, Phase I–II oncology trials take the form of dose-escalation studies, where initial subjects are treated at the lowest dose level and subsequent subjects are treated at progressively higher doses until the optimal dose is identified. While dose-escalation designs are well-motivated in the case of traditional chemotherapeutic agents, an alternate approach may be considered for therapeutic cancer vaccines, where an investigator's main objective is to evaluate the safety and efficacy of a set of dosing schedules or adjuvant combinations rather than to compare the safety and efficacy of progressively higher dose levels. We present a two-stage, Bayesian adaptive Phase I–II trial design to evaluate the safety and efficacy of therapeutic cancer vaccines. In the first stage, we determine whether a vaccination schedule achieves a minimum level of performance by comparing the toxicity and immune response rates to historical benchmarks. Vaccination schedules that achieve a minimum level of performance are compared using their magnitudes of immune response. If the superiority of a single schedule cannot be established after the first stage, Bayesian posterior predictive probabilities are used to determine the additional sample size required to identify the optimal vaccination schedule in a second stage.

AB - Phase I–II clinical trials refer to the class of designs that evaluate both the safety and efficacy of a novel therapeutic agent in a single trial. Typically, Phase I–II oncology trials take the form of dose-escalation studies, where initial subjects are treated at the lowest dose level and subsequent subjects are treated at progressively higher doses until the optimal dose is identified. While dose-escalation designs are well-motivated in the case of traditional chemotherapeutic agents, an alternate approach may be considered for therapeutic cancer vaccines, where an investigator's main objective is to evaluate the safety and efficacy of a set of dosing schedules or adjuvant combinations rather than to compare the safety and efficacy of progressively higher dose levels. We present a two-stage, Bayesian adaptive Phase I–II trial design to evaluate the safety and efficacy of therapeutic cancer vaccines. In the first stage, we determine whether a vaccination schedule achieves a minimum level of performance by comparing the toxicity and immune response rates to historical benchmarks. Vaccination schedules that achieve a minimum level of performance are compared using their magnitudes of immune response. If the superiority of a single schedule cannot be established after the first stage, Bayesian posterior predictive probabilities are used to determine the additional sample size required to identify the optimal vaccination schedule in a second stage.

KW - Bayesian adaptive design

KW - multiple outcomes

KW - phase I–II

KW - randomized trial

KW - therapeutic cancer vaccines

KW - two-stage

UR - http://www.scopus.com/inward/record.url?scp=85000797864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85000797864&partnerID=8YFLogxK

U2 - 10.1002/sim.7087

DO - 10.1002/sim.7087

M3 - Article

VL - 36

SP - 43

EP - 53

JO - Statistics in Medicine

JF - Statistics in Medicine

SN - 0277-6715

IS - 1

ER -